Literature DB >> 862204

Fasting hyperglycaemia and relatively unimpaired meal responses in mild diabetes.

R C Turner, J I Mann, R D Simpson, E Harris, R Maxwell.   

Abstract

Plasma glucose, insulin and triglyceride changes in response to a standard breakfast and an oral glucose tolerance test have been studied in normal, obese and diabetic subjects. Mild diabetics with an abnormal oral glucose tolerance test may have normal or near-normal incremental glucose responses to a standard breakfast. A raised fasting plasma glucose is the predominant day-to-day glucose abnormality of mild diabetes. Diabetics have decreased insulin responses to oral glucose compared with the meal, and the deficient insulin response to glucose probably accounts for both the raised fasting plasma glucose levels and the abnormal oral GTT. The initial insulin response to a meal is normal in mild diabetics, and is probably stimulated by secretogogues other than glucose. The oral glucose tolerance test is apposite for the diagnosis of diabetes in view of the impaired insulin response to glucose, but accurate measurement of the basal plasma glucose may be of equal value. The diabetic and obese subjects had normal triglyceride levels, and there was no detectable impairment of disposal of the exogenous triglyceride following the breakfast.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862204     DOI: 10.1111/j.1365-2265.1977.tb02009.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  2 in total

Review 1.  When to use insulin in the maturity onset diabetic.

Authors:  R B Tattersall; A R Scott
Journal:  Postgrad Med J       Date:  1987-10       Impact factor: 2.401

2.  Comparison of the metabolic effects of mixed meal and standard oral glucose tolerance test on glucose, insulin and C-peptide response in healthy, impaired glucose tolerance, mild and severe non-insulin-dependent diabetic subjects.

Authors:  S Marena; G Montegrosso; F De Michieli; E Pisu; G Pagano
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.